Introduction
A renewed interest in staphylococcal infections has emerged in recent years, since staphylococci resistant to multiple antibiotics have been reported with increasing frequency worldwide. Depending on local epidemiological conditions, a significant number of isolates are resistant to methicillin, lincosamides, macrolides, aminoglycosides and/or fluoroquinolones. [1] [2] [3] Because glycopeptides are the major drugs with reliable activity against methicillin-resistant strains of Staphylococcus aureus (MRSA), the emergence of S. aureus strains with intermediate resistance to glycopeptides has heightened the fears of pan antibioticresistant strains. 4 Thus, alternatives to the available antimicrobials are needed, not only for the treatment of infections due to multiply resistant strains, but also to reduce the increasing selection pressure on Gram-positive pathogens in hospitals.
The ketolides are a new class of macrolide antibiotics with a keto group replacing the L-cladinose moiety in position 3 and an alkyl-aryl extension at positions 11 and 12 of the lactone ring. The ketolides have activity against a broad range of pathogens, particularly against all major respiratory pathogens, including Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. 5, 6 However, data on the activity of ABT-773 against staphylococci are limited.
The aims of this study were: (i) to evaluate the activity of ABT-773 against a large number of different and wellcharacterized staphylococcal species, particularly against clonally different methicillin-resistant strains isolated from several geographical locations in Germany, including strains expressing different macrolide-lincosamide-streptogramin B (MLS B ) resistance phenotypes; and (ii) to compare the in vitro anti-staphylococcal activity of this novel ketolide with the macrolides erythromycin and clarithromycin.
Materials and methods
A total of 336 staphylococcal strains freshly isolated from clinical specimens were tested. The strains were isolated from blood or from other specimens, for example from foreign bodies, and were only included if they were considered aetiologically relevant. A large number of isolates were collected during the course of two multicentre studies, comprising 21 and 32 university and community hospitals in Germany. 7, 8 Only one isolate per patient was tested. As MRSA may cause outbreaks, we used several other criteria to avoid including multiple isolates of the same strain: first, isolates were collected over a period of years, which would make a single clone unlikely. Secondly, isolates were collected from different geographical locations in Germany, which would also reduce the chance of obtaining a single clone, and finally, when S. aureus isolates with similar antibiograms and phenotypes were obtained, we carried out pulsed-field gel electrophoresis (PFGE) and selected only one example of each strain.
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Comparative in vitro activity of ABT-773 and two macrolides against staphylococci The staphylococci were identified from a variety of conventional phenotypic characteristics and by using the API-Staph system (ATB32 Staph; bioMérieux, Marcy l'Étoile, France). To test for inducible and constitutive expression of macrolide-lincosamide (ML) resistance, the disc diffusion test was carried out as defined classically using erythromycin (15 g) and clindamycin (10 g) discs (Oxoid Ltd, Basingstoke, UK) without delineating subdivisions. 3 For this purpose, an aqueous suspension of bacterial growth from blood agar was adjusted to McFarland 0.5, and inoculated by swab on Mueller-Hinton agar (Difco, Augsburg, Germany). The arrangement of the discs allowed both the susceptibility pattern to individual compounds and interactions between both antibiotics to be observed with a minimal amount of repetition. As described previously, zones were interpreted according to their size and shape as indicating susceptible or resistant, the latter being inducible if a 'D'-shaped zone was observed (the compound on the left being the inducer). 3 Isolates were confirmed to be methicillin resistant by supplementation of the agar with 2% NaCl (using 5 g oxacillin discs results were read after incubation for 48 h at 30ЊC) and by detection of the mecA gene in strains with non-definable resistance phenotype as reported previously. 9 The MICs were determined on Mueller-Hinton agar, using the agar dilution technique with a final inoculum of c. 10 4 per spot. The following antimicrobial agents were used and obtained from their respective manufacturers: ABT-773, erythromycin, clarithromycin, quinupristin-dalfopristin. With the exception of quinupristin-dalfopristin, the compounds were tested in 13 different concentrations ranging from 0.031 to 128 mg/L. Quinupristin-dalfopristin was tested in eight different concentrations ranging from 0.06 to 8 mg/L. The results were read after 18 h incubation at 36ЊC. Table 2 . Again, ABT-773 was the most active antimicrobial agent tested against all CoNS including 58 methicillinresistant strains belonging to the species S. epidermidis and S. haemolyticus. All clindamycin-susceptible strains, as well as 29 CoNS with inducible MLS B phenotype, were susceptible to ABT-773 and were inhibited by a concentration of р0.063 mg/L. As for S. aureus, the activity of ABT-773 remained fully unchanged, irrespective of the resistance phenotype for methicillin. However, all CoNS with constitutive MLS B expression were resistant with MICs Ͼ 128 mg/L. Among the macrolides, clarithromycin revealed higher in vitro activity compared with erythromycin, with clarithromycin being slightly more active against S. haemolyticus strains. All CoNS tested were inhibited by р2 mg/L of quinupristin-dalfopristin (MIC 90 , 1 mg/L). The activity of ABT-773 remained unchanged irrespective of the MICs for the streptogramin tested. Quality control of all MIC determinations was carried out using the reference strains mentioned above. The MICs for these strains were within acceptable limits throughout testing. For example, for S. aureus ATCC 25923 the MICs (mg/L) were: quinupristin-dalfopristin, 1; erythromycin, 0.125; clarithromycin, р0.031; ABT-773, р0.031.
Discussion
The current empirical treatment of infections is challenged by the emerging resistance among the major pathogens. Over the last two decades, the incidence of infections particularly caused by multidrug-resistant Gram-positive bacteria has increased despite advances in antibacterial therapy. S. aureus as well as CoNS reveal a remarkable propensity for resistance to various antibiotics due to defined resistance mechanisms.
10,11 Thus, there continues to be a need for highly active antimicrobial agents, above all for the therapy of infections due to multidrug-resistant staphylococci.
In this context, the ability of the ketolide ABT-773 to inhibit staphylococci with an inducible MLS B resistance phenotype may be of major clinical importance. All strains that were clindamycin susceptible or showed the inducible type of MLS B resistance were inhibited by р0.063 mg/L of ABT-773, irrespective of the methicillin resistance phenotype.
In previous studies testing the activity of ABT-773 against staphylococci, multiple isolates of the same strain were not excluded by phenotypic or genomic typing. In addition, isolates were not classified previously regarding their MLS B phenotype. 5, 12, 13 Thus, our results for methicillin-resistant strains differ from those of previous investigations in which methicillin-susceptible strains (MIC 90 s 0.03-0.06 mg/L) were generally found to be more susceptible to ABT-773 than methicillin-resistant strains (MIC 90 s Ͼ16-128 mg/L). 5, 13 In our study, we tested a large number of clonally unrelated strains. This is particularly important for MRSA, which often cause at least regional outbreaks with the same strain. Furthermore, a broad spectrum of different, welldefined staphylococcal species was included in the testing.
Overall, the newly developed agent ABT-773 was highly active against both methicillin-susceptible and resistant strains with inducible MLS B resistance, stimulating further evaluation of these agents for therapy of infections due to staphylococci. However, strains with constitutive type of MLS B resistance are not in the spectrum of this ketolide. Therefore, an accurate knowledge of the local susceptibility pattern will be necessary if ABT-773 is to be used as empirical therapy for infections thought to be caused by multi-resistant S. aureus.
